Xenon Pharmaceuticals CFO acquires 7,500 shares

The award was granted October 15, 2025, and vests 25% on each of its first four anniversaries.

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. Chief Financial Officer Thomas Patrick Kelly acquired 7,500 common shares when 7,500 restricted share units vested on October 15, 2026. The award was granted October 15, 2025, and vests 25% on each of the first four anniversaries, beginning October 15, 2026. Kelly directly held 22,500 common shares following the transaction. No Rule 10b5-1 plan is reported.

Insider Trade Summary

7,500 shares exercised/converted

Exercise 2 txns

Insider Kelly Thomas Patrick

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units F1	7,500	$0.00	$0.00
Exercise	Common Shares F1	7,500	--	--

Holdings After Transaction: Restricted Share Units — 22,500 contracts (Direct); Common Shares — 22,500 shares (Direct)

Footnotes (1)

1. F1. Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on October 15, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026.

Key Figures

Restricted share units vested: 7,500 restricted share units Common shares acquired: 7,500 common shares Common shares following transaction: 22,500 common shares +1 more

4 metrics

Restricted share units vested 7,500 restricted share units October 15, 2026

Common shares acquired 7,500 common shares October 15, 2026

Common shares following transaction 22,500 common shares Direct holdings following the October 15, 2026 transaction

Vesting percentage 25% On each of the first four anniversaries, beginning October 15, 2026

Key Terms

restricted share unit, vests, derivative security

3 terms

restricted share unit financial

"under a restricted share unit ("RSU") award"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

vests financial

"award vests 25% on each of the first four anniversaries"

derivative security technical

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many XENE shares did CFO Thomas Patrick Kelly acquire?

Thomas Patrick Kelly acquired 7,500 common shares on October 15, 2026, when 7,500 restricted share units vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/16/2026 - 08:22 PM EDT Accepted by SEC EDGAR 10/16/2026 - 08:22 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Thomas Patrick

(Last) (First) (Middle)

3650 GILMORE WAY

(Street)

BURNABY V5G 4W8

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xenon Pharmaceuticals Inc. [ XENE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	10/15/2026		M		7,500(1)	A	(1)	22,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	10/15/2026		M			7,500	(1)	(1)	Common Shares	7,500	$0	22,500	D

Explanation of Responses:

1. Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on October 15, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on October 15, 2026.

	/s/ Nathaniel Adams, Attorney-in-fact	10/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)